JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor ( CSF-1R or cFMS , type III receptor tyrosine kinase), with IC 50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis In Vivo JTE-952 (3 mg/kg, p.o. once-daily) treatment reduces the overall progression of the clinical score, including inflammation and bone erosion in mouse model of collagen-induced arthritis (CIA model) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mouse model of collagen-induced arthritis (CIA model) . Dosage: 3 mg/kg. Administration: Oral once-daily. Result: Reduced the overall progression of the clinical score, including inflammation and bone erosion. Form:Solid IC50& Target:IC50: 13 nM (CSF1R), 261 nM (TrkA)